SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending intensely right now ahead of its earnings report, with community focus on its massive AI infrastructure investments and significant debt levels. Investors are debating if robust cloud growth and demand for AI compute will offset concerns over capital expenditure and conflicting reports about the status of a major data center expansion deal.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, marking a significant turnaround that has the community anticipating a potential short squeeze. Investors are highlighting the company's battery-as-a-service model and new in-house chip developments, drawing comparisons to other major EV players' early growth.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following impressive Q4 financial results, which showcased strong revenue growth from its rare disease drug MIPLYFFA and a significant shift to profitability, sparking community discussions about its re-valuation as a commercial-stage enterprise. Anticipation for European approval of MIPLYFFA, coupled with increased analyst price targets and high trading volume, is fueling speculation among investors.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

HGRAF is surging amid regulatory clearances for its ultra-pure graphene in key markets and anticipation of its Austin facility launch and NASDAQ uplisting, with the community actively debating its potential to revolutionize industries and secure major commercial contracts.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech is drawing strong attention and trading volume following its virtual investor conference, with the community focused on its unique EPA Safer Choice certified fire retardant technology as a significant regulatory moat and its potential in the expanding wildfire prevention and building materials sectors.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to widespread community frustration and confusion surrounding its announced proposed convertible senior notes offering, with many questioning management's strategic intentions for raising capital despite existing substantial cash reserves and speculating on possible institutional arbitrage plays.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is making new all-time highs and fueling bullish community sentiment following its transformative acquisition of Covelya Group, integrating key subsea technologies to become a dominant player in underwater defense and marine infrastructure. Investors are actively discussing its strategic expansion, crucial partnerships, and potential future NASDAQ uplisting.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical anxiety following reports of Iran preparing to deploy naval mines in the Strait of Hormuz, which immediately impacts oil prices and global shipping. This development is intensifying market volatility and community debate, especially given the administration's conflicting messages on the conflict's status.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics (PLYX), a clinical-stage biotech focusing on rare diseases, is highly volatile following its announcement of a CRO selection for its PLX-200 Phase 2 trial, sparking intense community speculation around short squeeze potential given its low float and direct listing structure.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply as Novo Nordisk dropped its patent lawsuit, paving the way for Hims to sell Ozempic and Wegovy, sparking intense community discussion about a potential short squeeze and a re-evaluation of its long-term growth in the GLP-1 market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial.</li><li>The firm said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets.</li><li>The company said that&nbsp;&nbsp;Early safety evaluations showed the product was well tolerated, with no adverse events reported.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) shot up 32% on Wednesday after the company said it received favorable feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational new drug (IND) meeting for OTASA, its high-dose sublingual (under-the-tongue) aspirin aimed at emergency treatment of suspected heart attacks.The FDA’s feedback supports a planned Section 505(b)(2) New Drug Application (NDA) submission in the second half of 2026, the company added.Based on the agency’s guidance, Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. The study will enroll 32 healthy volunteers and compare OTASA 162 mg with the current standard of care, two chewed 81 mg aspirin tablets, by measuring inhibition of serum thromboxane B2, a marker linked to blood clotting.The pre-IND submission was supported by encouraging pilot clinical data. Aspire said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets. The sublingual formulation also achieved rapid platelet inhibition, reducing thromboxane B2 levels within the first two minutes after administration. Early safety evaluations showed the product was well tolerated, with no adverse events reported.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ASBP_jpg_d2fe432dd1.webp" alt="ASBP.jpg" width="906" height="105"><figcaption>&nbsp;</figcaption></figure>Users speculated that the company could already be engaged in licensing negotiations.<stembedurl>https://stocktwits.com/juned/message/641088627</stembedurl><stembedurl>https://stocktwits.com/Pennystockmadness/message/641086670</stembedurl><h2 class="st-heading-2">Stock Price</h2>The update and the subsequent rally in stock price come at a time when the company has been dealing with listing concerns stemming from its low share price. In November, investors approved a proposal allowing the board to implement a reverse stock split at a ratio of 1-for-5 to 1-for-40, within one year if needed.The company has also secured Nasdaq approval to remain listed, contingent on meeting minimum bid price and equity requirements by late January and mid-February 2026.At present, the stock is trading near the $0.14 mark.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-falls-ahead-of-index-fund-rebalancing/cmxz3OLR420">Silver Tumbles 5% Amid Profit-Booking And&nbsp;Scheduled Reshuffling Of Commodity Index Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Equity

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Aspire Biopharma Holdings Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

ASBP
Aspire Biopharma Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ASBP News

ASBPAspire Biopharma Holdings Inc